May 05, 2026

Abiraterone Plus Olaparib Shows ‘Remarkable’ Survival in BRCA/ATM-Mutated Metastatic Castration-Resistant Prostate Cancer

Updated results from the phase II BRCAAway trial showed that first-line treatment with abiraterone and prednisone plus olaparib resulted in a median overall survival of more than 5 years in patients w...

The ASCO Post

May 04, 2026

COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings

Patients diagnosed with metastatic breast cancer and non–small cell lung cancer had longer survival compared to national benchmarks when treated in independent community oncology practices, according ...

The ASCO Post

May 04, 2026

Zoldonrasib in Patients With KRAS G12D–Mutant NSCLC Previously Treated With Chemoimmunotherapy

The investigational KRAS G12D inhibitor zoldonrasib had a favorable safety profile and induced antitumor activity in some patients with KRAS G12D–mutated non–small cell lung cancer (NSCLC) who were pr...

The ASCO Post

April 30, 2026

Belzutifan/Lenvatinib Outperforms Cabozantinib After Checkpoint Inhibitors in Advanced Renal Cell Carcinoma

At the first and second interim analyses of the phase III LITESPARK-011 trial, treatment with the novel first-in-class hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor belzutifan plus lenvatinib im...

The ASCO Post

April 30, 2026

Acupuncture for Nocturia in Survivors of Prostate Cancer

Guest Editor’s Note: Nocturia, waking up from sleep more than once to urinate, is prevalent in survivors of prostate cancer and is associated with a diminished quality of life and a higher mortality t...

The ASCO Post

April 29, 2026

AI-Powered, Next-Generation Sequencing Blood-Based Assay Evaluated for Detection of Post-HCT Relapse in AML and MDS

Monitoring for relapse with an artificial intelligence (AI)-powered peripheral blood-based tool called AlloHeme demonstrated greater sensitivity in predicting relapse after hematopoietic cell transpla...

The ASCO Post

April 29, 2026

MIBC: Pembrolizumab With Trimodal Therapy for Bladder Preservation

Pembrolizumab in combination with gemcitabine and concurrent hypofractionated radiation therapy and maximal transurethral resection may be safe and feasible in patients with muscle-invasive bladder ca...

The ASCO Post

April 28, 2026

Neoadjuvant Durvalumab and Chemotherapy in Triple-Negative Breast Cancer: Long-Term Follow-Up of GeparNuevo Trial

As reported in the Journal of Clinical Oncology by Loibl et al, long-term analysis of the German phase II GeparNuevo trial showed continued benefit in outcomes with neoadjuvant durvalumab vs placebo f...

The ASCO Post

April 28, 2026

Proton Therapy in Early-Onset Locally Advanced Rectal Cancer: The Importance of Fertility-Preserving Multimodality Care

The rising incidence and mortality of early-onset colorectal cancer (EOCRC), defined as disease occurring in patients younger than 50, has emerged as a clinically significant trend with implications for screening, diagnosis, and survivorship.

Baptist Health South Florida

April 27, 2026

Clinical Strategies for Preserving Fertility in Male Cancer Patients

Urologist Justin Dubin, M.D., director of Men’s Sexual Health at Baptist Health Miami Cancer Institute, emphasizes that fighting cancer and preserving fertility are not mutually exclusive.

Baptist Health South Florida